In vitro evaluation of the effectiveness of the macrolide rokitamycin and chlorpromazine against Acanthamoeba castellanii

Antimicrobial Agents and Chemotherapy

Volumn 48, Issue 12, 2004, Pages 4520-4527

  Mattana, A ^a   Biancu, G ^a   Alberti, L ^a   Accardo, A ^a   Delogu, G ^a   Fiori, P L ^a   Cappuccinelli, P ^a  

^a UNIVERSITY OF SASSARI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; AMPHOTERICIN B; ANTIBIOTIC AGENT; ANTIPROTOZOAL AGENT; ANTIVIRUS AGENT; CHLORPROMAZINE; ERYTHROMYCIN; FUSIDIC ACID; MACROLIDE; NEUROLEPTIC AGENT; ORNIDAZOLE; PEFLOXACIN; POLYMYXIN B; ROKITAMYCIN; SURAMIN; ZIDOVUDINE;

ACANTHAMOEBA CASTELLANII; ARTICLE; CONTROLLED STUDY; CORNEA; CYTOPATHOGENIC EFFECT; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; GROWTH CURVE; LOW DRUG DOSE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; TROPHOZOITE;

ACANTHAMOEBA; AMEBIASIS; AMEBICIDES; ANIMALS; CELLS, CULTURED; CHLORPROMAZINE; CORNEA; DRUG SYNERGISM; HUMANS; MIOCAMYCIN;

EID: 9644268987     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.48.12.4520-4527.2004     Document Type: Article

References (44)

1. Amaral, L., J. E. Kristiansen, M. Viveiros, and J. Atouguia. 2001. Activity of phenothiazines against antibiotic-resistant Mycobacterium tuberculosis: a review supporting further studies that may elucidate the potential use of thioridazine as anti-tuberculosis therapy. J. Antimicrob. Chemother. 47:505-511.
2. Baldessarino R. J. 1980. Drugs and treatment of psychiatric disorders, p. 391-447. In L. S. Goodmann and A. Gilman (ed.), The pharmacological basis of therapeutics, 6th ed. McMillan Publishing Co., New York, N.Y.
3. Biddick, C. J., L. H. Rogers, and T. J. Brown. 1984. Viability of pathogenic and nonpathogenic free-living amoebae in long-term storage at a range of temperatures. Appl. Environ. Microbiol. 48:859-860.
4. Di Gregorio, C., F. Rivasi, M. Mongiardo, B. De Rienzo, S. Wallace, and G. S. Visvesvara. 1992. Acanthamoeba meningoencephalitis in an AIDS patient: first report from Europe. Arch. Pathol. Lab. Med. 116:1363-1365.
5. Eilam, Y., I. Polacheck, G. Bengigi, and P. Chernichovsky. 1987. Activity of phenothiazines against medically important yeasts. Antimicrob. Agents Chemother. 31:834-836.
6. Ferrante, A. 1991. Free-living amoebae: pathogenicity and immunity. Parasite Immunol. 13:31-47.
7. Fichera, M. E., M. K. Bhopale, and D. S. Ross. 1995. In vitro assays elucidate peculiar kinetics of clindamycin action against Toxoplasma gondii. Antimicrob. Agents Chemother. 39:1530-1537.
8. Friedland, L. R., S. A. Raphael, E. S. Deutsch, J. Johal, L. J. Martin, G. S. Visvesvara, and H. Lischner. 1992. Disseminated Acanthamoeba infection in a child with symptomatic human immunodeficiency virus infection. Pediatr. Infect. Dis. 11:404-407.
9. Garcia, L. S., and D. A. Bruckner. 1993. Diagnostic medical parasitology, 2nd ed., p. 601-605. American Society for Microbiology, Washington, D.C.
10. Gayatri, R., and S. Chatterjee. 1991. Effects of chlorpromazine on growth and development of Dictyostelium discoideum. Microbios 68:97-107.
11. Georgopoulos A., K. F. Linnau, A. Buxbaum, C. Coste, M. A. Ramirez de Los Santos, A. Shabpar, and W. Graninger. 2001. Efficacy of macrolides vs. metronidazole against Entamoeba histolytica clinical isolates. Wien. Klin. Wochenschr. 113:593-596.
12. Giacometti, A., O. Cirioni, F. Barchiesi, F. Ancarani, and G. Scalise. 2000. Activity of nitazoxanide alone and in combination with azithromycin and rifabutin against Cryptosporidium parvum in cell culture. J. Antimicrob. Chemother. 45:453-456.
13. Goswick, S. M., and G. M. Brenner. 2003. Activities of azithromycin and amphotericin B against Naegleria fowleri in vitro and in a mouse model of primary amoebic meningoencephalitis. Antimicrob. Agents Chemother. 47:524-528.
14. Hattori, N., M. O. Nakajiama, K. O'Hara, and T. Sawai. 1998. Novel antibiotic susceptibility tests by the ATP-bioluminescence method using filamentous cell treatment. Antimicrob. Agents Chemother. 42:1406-1411.
15. Ishiguro, M., H. Koga, S. Kohno, T. Hayashi, K. Yamaguchi, and M. Hirota. 1989. Penetration of macrolides into human polymorphonuclear leucocytes. J. Antimicrob. Chemother. 24:719-729.
16. Jeansson, S., and T. K. Kvien. 2001. Acanthamoeba polyphaga in rheumatoid arthritis: possibility for a chronic infection. Scand. J. Immunol. 53:610-614.
17. Kalkanidis, M., N. Klonis, L. Tilley, and L. W. Deady. 2002. Novel phenothiazine antimalarials: synthesis, antimalarial activity, and inhibition of the formation of beta-haematin. Biochem. Pharmacol. 63:833-842.
18. Kilvington, S. 1989. Moist-heat disinfection of Acanthamoeba cysts. Lett. Appl. Bacteriol. 9:187-189.
19. Kim, B. G., P. P. McCann, and T. J. Byers. 1987. Inhibition of multiplication in Acanthamoeba castellanii by specific inhibitors of ornithine decarboxylase. J. Protozool. 34:264-266.
20. Koide, J., E. Okusawa, T. Ito, S. Mori, T. Takeuchi, S. Itoyama, and T. Abe. 1998. Granulomatous amoebic encephalitis caused by Acanthamoeba in a patient with systemic lupus erytrematosus. Clin. Rheumatol. 17:329-332.
21. Kotilainen, P., J. Jalava, O. Meurman, O. P. Lehtonen, E. Rintala, O. P. Seppala, E. Eerola, and S. Nikkari. 1998. Diagnosis of meningoccocal meningitis by broad-range bacterial PCR with cerebrospinal fluid. J. Clin. Microbiol. 36:2205-2209.
22. Kotting, J., M. R. Berger, C. Unger, and H. Eibl. 1992. Alkylphosphocholines: influence of structural variations on biodistribution of antineoplastically active concentrations. Cancer Chemother. Pharmacol. 30:105-112.
23. Larkin, D. F. P., S. Klivington, and J. K. G. Dart. 1992. Treatment of Acanthamoeba keratitis with polyhexamethylene biguanide. Ophthalmology 99:185-191.
24. Levine, S., A. E. Goldstein, M. Dahdouh, P. Blank, C. Hoffman, and C. A. Gropper. 2001. Cutaneous Acanthamoeba in a patient with AIDS: a case study with a review of new therapy. Cutis 67:377-380.
25. Lim, L., D. J. Coster, and P. R. Badenoch. 2000. Antimicrobial susceptibility of 19 Australian corneal isolates of Acanthamoeba. Clin. Exp. Ophthalmol. 28:119-124.
26. Ma, P., G. S. Visvesvara, A. J. Martinez, F. H. Theodore, P. M. Daggett, and T. K. Sawyer. 1990. Naegleria and Acanthamoeba infections: review. Rev. Infect. Dis. 12:490-513.
27. Marciano-Cabral, F., R. Putfenbarger, and J. A. Cabral. 2000. The increasing importance of Acanthamoeba infections. J. Eukaryot. Microbiol. 47:29-36.
28. Murdoch, D., T. B. Gray, R. Cursons, and D. Parr. 1998. Acanthamoeba keratitis in New Zealand, including two cases with in vivo resistance to polyhexamethylene biguanide. Aust. N. Z. J. Ophthalmol. 26:231-236.
29. Ofori-Kwakye, S. K., D. G. Sidebottom, J. Herbert, E. G. Fischer, and G. S. Visvesvara. 1986. Granuiomatous brain tumor caused by Acanthamoeba. Case report. J. Neurosurg. 64:505-509.
30. Ondarza, R. N., E. Hernandez, A. Iturbe, and G. Hurtado. 2000. Inhibitory and lytic effects of phenothiazine derivatives and related tricyclic neuroleptic compounds, on Entamoeba histolytica HK9 and HM1 trophozoites. Biotechnol. Appl. Biochem. 32:61-67.
31. Perrine, D., J. P. Chenu, P. Georges, J. C. Lancelot, C. Saturnino, and M. Robba. 1995. Amoebicidal efficiencies of various diamidines against two strains of Acanthamoeba polyphaga. Antimicrob. Agents Chemother. 39:339-342.
32. Saragoza, R. 1994. Ecology of free-living amoebae. Crit. Rev. Microbiol. 20:225-241.
33. Schuster, F. L., and N. Mandel. 1984. Phenothiazine compounds inhibit in vitro growth of pathogenic free-living amoebae. Antimicrob. Agents Chemother. 25:109-112.
34. Schuster, F. L., and G. S. Visvesvara. 1998. Efficacy of novel antimicrobials against clinical isolates of opportunistic amoebas. J. Eukaryot. Microbiol. 45:612-618.
35. Seal, D. V., J. Hay, and C. M. Kirkness. 1995. Chlorhexidine or polyhexamethylene biguanide for Acanthamoeba keratitis. Lancet 345:136.
36. Seijo-Martinez M., G. Gonzalez-Mediero, P. Santiago, A. Rodriguez de Lope, J. Diz, C. Conde, and G. S. Visvesvara. 2000. Granulomatous amoebic encephalitis in a patient with AIDS: isolation of Acanthamoeba sp. group II from brain tissue and successful treatment with sulfadiazine and fluconazole. J. Clin. Microbiol. 38:3892-3895.
37. Selby, D., R. S. Chandra, T. A. Rakusan, B. Loechelt, B. M. Markle, and G. S. Visvesvara. 1998. Amoebic osteomyelitis in a child with acquired immunodeficiency syndrome: a case report. Pediatr. Pathol. Lab. Med. 18: 89-95.
38. Sharma, S., H. Kaur, and G. K. Khuller. 2001. Cell cycle effects of the phenothiazines: trifluoperazine and chlorpromazine in Candida albicam. FEMS Microbiol. Lett. 199:185-190.
39. Tasaka, Y., M. Sumi, Y. Niki, and R. Soejima. 1988. Rokitamycin uptake by alveolar macrophages. Jpn. J. Antibiot. 41:836-840.
40. Teknos, T. N., M. D. Poulin, A. M. Laruentano, and K. K. Li. 2000. Acanthamoeba rhinosinusitis: characterization, diagnosis, and treatment. Am. J. Rhinol. 14:387-391.
41. Torno, M. S., Jr., R. Babapour, A. Gurevitch, and M. D. Witt. 2000. Cutaneous acanthamoebiasis in AIDS. J. Am. Acad. Dermatol. 42:351-354.
42. Turner, N. A., A. D. Russell, J. R. Furr, and D. Lloid. 2000. Emergence of resistance to biocides during differentiation of Acanthamoeba castellanii. J. Antimicrob. Chemother. 46:27-34.
43. Viveiros, M., and L. Amaral. 2001. Enhancement of antibiotic activity against poly-drug resistant Mycobacterium tuberculosis by phenothiazines. Int. J. Antimicrob. Agents 17:225-228.
44. Walochnik, J., M. Duchene, K. Seifert, A. Obwaller, T. Hottkowitz, G. Wiedermann, H. Eibl, and H. Aspock. 2002. Cytotoxic activities of alkylphosphocholines against clinical isolates of Acanthamoeba spp. Antimicrob. Agents Chemother. 46:695-701.